Dossier assessment
Ravulizumab - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Ravulizumab - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Ravulizumab - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adults with paroxysmal nocturnal haemoglobinuria (PNH)
Added benefit neither proven for patients with haemolysis and at least one clinical symptom indicative of high disease activity nor for clinically stable patients after at least 6 months of eculizumab treatment
Project details
- Project no.
- A19-59
- Commission
- Commission awarded on 01.08.2019 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Haematology
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Addendum
Ravulizumab (paroxysmal nocturnal haemoglobinuria) - Addendum to Commission A19-59
Status: Commission completed